文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

欧洲黏多糖贮积症Ⅰ型造血干细胞移植的结局:移植物失败的危险因素分析

Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure.

作者信息

Boelens J J, Wynn R F, O'Meara A, Veys P, Bertrand Y, Souillet G, Wraith J E, Fischer A, Cavazzana-Calvo M, Sykora K W, Sedlacek P, Rovelli A, Uiterwaal C S P M, Wulffraat N

机构信息

Department of Immunology/BMT, Wilhelmina Children's Hospital, Utrecht Medical Center, Utrecht, The Netherlands.

出版信息

Bone Marrow Transplant. 2007 Aug;40(3):225-33. doi: 10.1038/sj.bmt.1705718. Epub 2007 May 28.


DOI:10.1038/sj.bmt.1705718
PMID:17529997
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7094454/
Abstract

Hurler's syndrome (HS), the most severe form of mucopolysaccharidosis type-I, causes progressive deterioration of the central nervous system and death in childhood. Allogeneic stem cell transplantation (SCT) before the age of 2 years halts disease progression. Graft failure limits the success of SCT. We analyzed data on HS patients transplanted in Europe to identify the risk factors for graft failure. We compared outcomes in 146 HS patients transplanted with various conditioning regimens and grafts. Patients were transplanted between 1994 and 2004 and registered to the European Blood and Marrow Transplantation database. Risk factor analysis was performed using logistic regression. 'Survival' and 'alive and engrafted'-rate after first SCT was 85 and 56%, respectively. In multivariable analysis, T-cell depletion (odds ratio (OR) 0.18; 95% confidence interval (CI) 0.04-0.71; P=0.02) and reduced-intensity conditioning (OR 0.08; 95% CI 0.02-0.39; P=0.002) were the risk factors for graft failure. Busulfan targeting protected against graft failure (OR 5.76; 95% CI 1.20-27.54; P=0.028). No difference was noted between cell sources used (bone marrow, peripheral blood stem cells or cord blood (CB)); however, significantly more patients who received CB transplants had full-donor chimerism (OR 9.31; 95% CI 1.06-82.03; P=0.044). These outcomes may impact the safety/efficacy of SCT for 'inborn-errors of metabolism' at large. CB increased the likelihood of sustained engraftment associated with normal enzyme levels and could therefore be considered as a preferential cell source in SCT for 'inborn errors of metabolism'.

摘要

黏多糖贮积症 I 型最严重的形式——胡勒氏综合征(HS),会导致中枢神经系统进行性恶化,并在儿童期死亡。2岁前进行异基因干细胞移植(SCT)可阻止疾病进展。移植物失败限制了SCT的成功率。我们分析了在欧洲接受移植的HS患者的数据,以确定移植物失败的危险因素。我们比较了146例接受不同预处理方案和移植物的HS患者的结局。患者于1994年至2004年间接受移植,并登记到欧洲血液与骨髓移植数据库。使用逻辑回归进行危险因素分析。首次SCT后的“生存率”和“存活并植入率”分别为85%和56%。在多变量分析中,T细胞去除(比值比(OR)0.18;95%置信区间(CI)0.04 - 0.71;P = 0.02)和减低强度预处理(OR 0.08;95% CI 0.02 - 0.39;P = 0.002)是移植物失败的危险因素。白消安靶向治疗可预防移植物失败(OR 5.76;95% CI 1.20 - 27.54;P = 0.028)。所用细胞来源(骨髓、外周血干细胞或脐带血(CB))之间未发现差异;然而,接受CB移植的患者中有更多比例具有完全供体嵌合现象(OR 9.31;95% CI 1.06 - 82.03;P = 0.044)。这些结果可能会对总体上SCT治疗“先天性代谢缺陷”的安全性/有效性产生影响。CB增加了与正常酶水平相关的持续植入的可能性,因此在SCT治疗“先天性代谢缺陷”时可被视为优先选择的细胞来源。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a33/7094454/095d247b2da5/41409_2007_Article_BF1705718_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a33/7094454/d785b70553db/41409_2007_Article_BF1705718_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a33/7094454/095d247b2da5/41409_2007_Article_BF1705718_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a33/7094454/d785b70553db/41409_2007_Article_BF1705718_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a33/7094454/095d247b2da5/41409_2007_Article_BF1705718_Fig2_HTML.jpg

相似文献

[1]
Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure.

Bone Marrow Transplant. 2007-8

[2]
Cord-blood transplants from unrelated donors in patients with Hurler's syndrome.

N Engl J Med. 2004-5-6

[3]
Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome.

Biol Blood Marrow Transplant. 2009-5

[4]
Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources.

Bone Marrow Transplant. 2003-6

[5]
Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major.

Pediatr Blood Cancer. 2013-2-19

[6]
A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.

Biol Blood Marrow Transplant. 2011-11-9

[7]
Unrelated CD3/CD19-depleted peripheral stem cell transplantation for Hurler syndrome.

Pediatr Hematol Oncol. 2014-11

[8]
Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.

Bone Marrow Transplant. 2006-2

[9]
Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.

Haematologica. 2000-8

[10]
Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen.

Bone Marrow Transplant. 2008-2

引用本文的文献

[1]
Diffusion tensor imaging with free-water correction reveals distinctions between severe and attenuated subtypes in Mucopolysaccharidosis type I.

J Inherit Metab Dis. 2025-1

[2]
Incidence and risk factors of graft failure in allogeneic hematopoietic stem cell transplantation for mucopolysaccharidosis in a nationwide pediatric cohort. A study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.

EJHaem. 2024-11-26

[3]
Allogeneic stem cell transplantation for inherited metabolic disorders: 35 years' experience at a single institution.

Int J Hematol. 2024-9

[4]
Long term follow-up after haematopoietic stem cell transplantation for mucopolysaccharidosis type I-H: a retrospective study of 51 patients.

Bone Marrow Transplant. 2023-3

[5]
The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Different Donors in Recipients With Mucopolysaccharidosis.

Front Pediatr. 2022-6-30

[6]
Allogeneic hematopoietic stem cell transplantation for inherited metabolic disorders.

Int J Hematol. 2022-7

[7]
Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?

Int J Mol Sci. 2022-4-27

[8]
Hematopoietic stem cell transplant for Hurler syndrome: does using bone marrow or umbilical cord blood make a difference?

Blood Adv. 2022-12-13

[9]
Genetically Modified Cell Transplantation Through Macroencapsulated Spheroids with Scaffolds to Treat Fabry Disease.

Cell Transplant. 2021

[10]
Burden of Morbidity after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A BMT Survivor Study Report.

Transplant Cell Ther. 2022-3

本文引用的文献

[1]
Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases.

Biol Blood Marrow Transplant. 2006-2

[2]
Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells.

Pediatr Res. 2006-2

[3]
Marrow stromal cells from patients affected by MPS I differentially support haematopoietic progenitor cell development.

J Inherit Metab Dis. 2005

[4]
Human umbilical cord blood progenitors: the potential of these hematopoietic cells to become neural.

Stem Cells. 2005

[5]
Mesenchymal stem cells avoid allogeneic rejection.

J Inflamm (Lond). 2005-7-26

[6]
Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.

Transpl Immunol. 2005-8

[7]
Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease.

N Engl J Med. 2005-5-19

[8]
Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation.

Biol Blood Marrow Transplant. 2005-5

[9]
New trends in umbilical cord blood transplantation.

Blood. 2005-5-15

[10]
Stem cell transplantation (cord blood transplants).

Hematology Am Soc Hematol Educ Program. 2004

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索